AstraZeneca and Ionis collaborate to develop antisense therapy apron tersen

AstraZeneca will pay up to $ 2.9 billion in sales-based milestone payments to Ionis. Credits: © AstraZeneca.

AstraZeneca and Ionis Pharmaceuticals have signed an agreement to develop and market the experimental treatment eplontersen, formerly known as IONIS-TTR-LRX.

Aprontelsen is a ligand-binding antisense therapy that can potentially reduce transthyretin (TTR protein) production for the treatment of hereditary and non-hereditary forms of TTR amyloidosis (ATTR).

Under the agreement, the parties will co-develop and co-sell eplontersen in the United States, and AstraZeneca will be responsible for global development and marketing activities outside of Latin America.


With regulatory approval, Ionis is entitled to an additional conditional payment from AstraZeneca of $ 200 million in advance, up to $ 485 million.

In addition, Ionis is eligible to receive up to $ 2.9 billion in sales-based milestone payments and region-based low double-digit royalty payments.

Under the agreement, Ionis will continue to manufacture and distribute apron tersen for ongoing clinical trials and process certification.

AstraZeneca oversees the commercial distribution of antisense therapy and the timing of the switch is determined by the company. The company is also in charge of selling products.

The transaction is expected to close in the fourth quarter of this year, subject to the required closing conditions and regulatory approvals.

Mene Pangalos, Executive Vice President of AstraZeneca BioPharmaceuticals R & D, said:

“Thanks to its precise liver-targeted properties, it may be the best-in-class treatment for patients suffering from this catastrophic disease and currently have limited options.”

Aprontelsen is currently being analyzed in Phase III clinical trials for the treatment of amyloid transthyretin cardiomyopathy (ATTR-CM) and amyloid transthyretin polyneuropathy (ATTR-PN).

February 2018, AstraZeneca has licensed Generation 2.5 antisense drug from Ionis For the treatment of kidney disease. AstraZeneca and Ionis collaborate to develop antisense therapy apron tersen

Back to top button